Transient transfection studies have shown that the probasin (PB) promoter confers androgen selectivity over other steroid hormones, and transgenic animal studies have demonstrated that the PB promoter will target androgen, but not glucocorticoid, regulation in a prostate-specific manner. Previous PB promoters either targeted low levels of transgene expression or became too large to be conveniently used. The goal was to design a PB promoter that would be small, yet target high levels of prostate-specific transgene expression. Thus, a composite probasin promoter (ARR 2 PB) coupled to the bacterial chloramphenicol acetyltransferase reporter (ARR 2 PBCAT) was generated and tested in prostatic and nonprostatic cell lines and in a transgenic mouse model. In PC-3, LNCaP, and DU145 prostate cancer cell lines, the ARR 2 PB promoter gave basal expression and was induced in response to androgen and glucocorticoid treatment after cotransfection with the respective steroid receptor. Basal expression of ARR 2 PBCAT in the nonprostatic COS-1, MCF-7, ZR-75-1, and PANC-1 cell lines was very low; however, CAT activity could be induced in response to androgens and glucocorticoids when cells were cotransfected with either the AR or GR. In contrast to the transfection studies, ARR 2 PBCAT transgene expression remained highly specific for prostatic epithelium in transgenic mice. CAT activity decreased after castration, and could be induced by androgens and, in addition, glucocorticoids. This demonstrates that the necessary sequences required to target prostate-specific epithelial expression are contained within the composite ARR 2 PB minimal promoter, and that high transgene expression can now be regulated by both androgens and glucocorticoids. The ARR 2 PB promoter represents a novel glucocorticoid inducible promoter that can be used for the generation of transgenic mouse models and in viral gene therapy vectors for the treatment of prostate cancer in humans. (Endocrinology 141: 4698 -4710, 2000) 
ARR 2 PBCAT in the nonprostatic COS-1, MCF-7, ZR-75-1, and PANC-1 cell lines was very low; however, CAT activity could be induced in response to androgens and glucocorticoids when cells were cotransfected with either the AR or GR. In contrast to the transfection studies, ARR 2 PBCAT transgene expression remained highly specific for prostatic epithelium in transgenic mice. CAT activity decreased after castration, and could be induced by androgens and, in addition, glucocorticoids. This demonstrates that the necessary sequences required to target prostate-specific epithelial expression are contained within the composite ARR 2 PB minimal promoter, and that high transgene expression can now be regulated by both androgens and glucocorticoids. The ARR 2 PB promoter represents a novel glucocorticoid inducible promoter that can be used for the generation of transgenic mouse models and in viral gene therapy vectors for the treatment of prostate cancer in humans. (Endocrinology 141: 4698 -4710, 2000) T HE ANDROGEN RECEPTOR (AR) is a potent regulator of gene transcription (1) (2) (3) (4) . One prostate-specific gene, probasin (PB), was isolated as an abundant protein from rat dorsolateral prostate nuclei (5) (6) (7) (8) (9) . Amino acid analysis revealed that PB belonged to the lipocalin superfamily, a family of ligand carrier proteins (8) . Immunohistochemical studies demonstrated that PB is localized to the nucleus of prostatic epithelial cells and in prostatic secretions (8) . The nuclear and secreted forms of the protein are translated from a bifunctional messenger RNA (mRNA), where initiation at the first AUG codon produces a protein with a signal peptide for secretion and initiation at the second AUG codon produces an intracellular protein that is truncated by the first 17 amino acids and transported into the nucleus (8) .
Androgens regulate the developmental expression of PB gene expression such that PB mRNA levels rise significantly in the prostatic lobes in parallel with increasing serum levels of androgens during the onset of sexual maturity (5, 10, 11) . Maximal levels of PB are maintained by androgens in the adult, and castration studies have demonstrated that within 7 days postcastration, PB mRNA levels decrease as the gland regresses (11) . In the castrated rat, PB mRNA levels rebound to intact levels between 12-15 days postcastration, suggesting that other factors may also regulate PB gene expression (11) .
In previous transient transfection and deoxyribonuclease I footprinting studies, two distinct AR-binding sites, ARBS-1 (located at position Ϫ236 to Ϫ223) and ARBS-2 (at position Ϫ140 to Ϫ117), were identified as being required for maximal androgen induction of chloramphenicol acetyltransferase (CAT) gene expression in the human PC-3 prostate cell line (6) . Neither binding site alone could induce CAT gene expression in response to androgen treatment. Also, androgenspecific transcriptional activation could not be reconstituted by linking two or three copies of either ARBS-1 or ARBS-2 alone (12) . A single point mutation in either ARBS prevented the AR from binding to both sites and eliminated androgeninduced biological activity (13) . Therefore, PB was androgen regulated when both AR binding sites were present in the wild-type (wt) configuration.
Androgen-selective activity was further characterized by comparing the relative binding affinities (K d ) of a purified synthetic peptide for the AR (AR2) or a synthetic peptide for the glucocorticoid receptor (GR; GR-DBD) on oligonucleotides for the consensus glucocorticoid response element (GRE) and the PB ARBS-1 or ARBS-2. As indicated in the band shift assays, the DNA binding affinity of the GR for either ARBS-1 or ARBS-2 was so low that it could not be determined, whereas the AR bound with high affinities for ARBS-1 and ARBS-2 (12) . Furthermore, the substitution of the C(3)1 gene GRE with the PB ARBS-2 element converted glucocorticoid regulation of C(3)1 gene transcription into an androgen-specific response (14) . As well, the PB ARBS-2 DNA element only recognized AR and not the glucocorticoid, mineralocorticoid, or progesterone receptors (15) . The determinant for receptor selectivity appeared to reside in the N-terminal part of the second zinc finger as well as in a four-residue C-terminal extension of the DNA-binding domain (15) . In PB gene expression, AR selectively binds ARBS-1 and ARBS-2 to regulate gene transcription, and together these two androgen-binding sites constitute the androgen response region (ARR) located between Ϫ244 to Ϫ96 bp of the PB promoter (12, 13) . The androgen-specific regulation of PB gene transcription and the prostatic epithelial cell specificity of PB gene transcription makes the promoter an ideal candidate to target transgenes to the prostate. Initial transgenic experiments used a small fragment of the PB promoter (Ϫ426 to ϩ28 bp) linked to the bacterial CAT reporter gene. Both developmental and hormonal regulation of CAT gene expression was restricted to the transgenic prostatic epithelium; however, the levels of transgene expression were modest (7). Castration studies also showed that CAT gene expression could be restored to precastration levels with androgen treatment, but that glucocorticoid treatment had no effect (7) . These data suggested that this small PB promoter lacked important enhancers that regulated PB gene expression. Therefore, a second transgenic model, using a large 12-kb PB promoter fragment (LPB) linked to the CAT gene was developed, which conferred high levels of androgen-regulated transgene expression to the transgenic prostate (16) . Immunohistochemical studies showed that LPB-CAT gene expression was epithelial cell specific and that transgene expression was increased dramatically over the Ϫ426/ϩ28PB promoter construct (16) . Again, castration studies demonstrated that CAT gene expression could be restored to precastration levels with androgen treatment, but that glucocorticoid treatment had no effect, indicating that no functional GRE was present within 12 kb of the PB promoter (16) .
In the current study we have developed a composite ARR 2 PB promoter that not only maintains prostate-specific transgene expression, but also provides a small promoter that reliably expresses high to very high transgene expression in transgenic mice. Indeed, the ARR 2 PB promoter resulted in high levels of transgene expression in 80% of the founders. This new construct offers a further advantage over the other PB promoter constructs in that it now exhibits glucocorticoid inducibility, and its small size makes it ideal to regulate any transgene even in viral vectors where size becomes a limiting problem.
Materials and Methods

Plasmid construction
The first step in the construction of the minimal PB promoters was the removal of sequences between Ϫ426 to Ϫ287. Two resulting PB promoter-CAT constructs were generated, one that spanned the endogenous PB promoter sequence from Ϫ244 to ϩ28 bp (Ϫ244PBCAT) and the other from Ϫ286 ϩ28 bp (Ϫ286PBCAT). Next, one or two copies of the PB ARR (Ϫ244 to Ϫ96 bp of the PB promoter, which encompasses one copy of ARBS-1 and one copy of ARBS-2 in the wild-type configuration) (12) were placed 5Ј to the Ϫ286PBCAT or to the shorter Ϫ244PBCAT construct.
Cell lines, media, and transient transfection assays
The human prostate carcinoma cell lines PC-3, LNCaP, and DU145; the monkey kidney cell line COS-1; the human breast carcinoma cell line MCF-7; the human pancreas carcinoma cell line PANC-1; and the human mammary gland carcinoma cell line ZR-75-1 were obtained from American Type Culture Collection (Manassas, VA). PC-3 cells were maintained in RPMI medium, 10% FBS, and 250 nm dexamethasone, and the other cell lines were cultured as recommended by American Type Culture Collection. For transient transfection assays, cells were plated at an initial density of 3-5 ϫ 10 5 /100-mm dish or 2-3 ϫ 10 4 /well in 24-well tissue culture plates and transfected by the calcium phosphate method as previously described (6) . Briefly, the cells were exposed to the DNA precipitate for 6 h, followed by removal of the medium and addition of steroids for 18 h. The rat AR (rAR) expression vector and the rat glucocorticoid receptor (rGR) expression vector were used in the transfection experiments. Both the rAR and rGR expression vectors use the simian virus 40 promoter to direct expression of these transgenes. The absolute level of protein expression from each vector may vary from cell line to cell line due to the concentrations of transcription factors that may regulate the simian virus 40 promoter and changes in stability of the mRNA and the stability of the receptor proteins. This can ultimately influence the level of induction of the reporter gene. The transfection conditions were initially optimized by cotransfecting mouse mammary tumor virus (MMTV)-CAT with increasing concentrations of rat AR and rat GR expression vectors (12) . These experiments determined that the optimal amounts of each steroid receptor expression vector were similar; therefore, all cotransfection experiments were performed using an equal concentration of plasmid (5 g/ml), which was the optimal rAR and rGR concentration for the maximal response of MMTV-CAT to dihydrotestosterone (DHT) or dexamethasone (DEX) treatment, respectively (12) . The cells transfected with PBCAT plasmids were harvested after 24 h of incubation from the beginning of the transfection, and CAT activity was determined by the two-phase fluor diffusion assay using [ 3 H]acetylcoenzyme (5.9 Ci/mmol; Amersham Pharmacia Biotech, Piscataway, NJ) as the substrate (6) . The transfection efficiency was determined by cotransfecting pRL-CMV containing the Renilla luciferase reporter gene (Promega Corp., Madison, WI). The luciferase activity was determined using the Promega Corp. luciferase assay system (E1980). The values plotted represent the mean of at least three individual samples Ϯ sd.
Establishment of ARR 2 PBCAT transgenic mouse lines
All animal studies were conducted in accordance with the principles and procedures outlined by Vanderbilt University council on animal care. From the experimental cell culture results, the ARR 2 PB construct was chosen for further study. The ARR 2 PBCAT transgenic mice were generated by microinjection of the DNA into the male pronucleus of a fertilized oocyte by the Transgenic Core/ES Cell Shared Resource of the Vanderbilt-Ingram Cancer Center. Four transgenic founders, three males and one female, were generated. Animals were housed in standard lighting (12 h of light, 12 h of darkness) and allowed food and water ad libitum. Transgenic animals were identified by PCR-based screening using isolated mouse tail DNA as described previously (16) , and the lines were maintained as the B6D2F1 mouse strain. Transgene copy number was determined by Southern blot and DNA slot blot hybridization (17) . Mouse genomic DNA from transgenic animals containing a single copy of the transgene, mouse epididymal retinoic acid-binding protein (RABP) promoter linked to the CAT transgene (mE-RABPCAT), served as an internal control (18) . A 1200-bp complementary DNA fragment of the CAT gene was used to detect the both the ARR 2 PBCAT and the mE-RABPCAT (control) transgene. In addition, as a further internal control, a 600-bp mE-RABP DNA fragment was used to detect the endogenous RABP gene. The DNA probes were labeled with [ 32 P]deoxy-CTP (3000 Ci/mmol; Amersham Pharmacia Biotech) using the Rediprimer II kit (Amersham Pharmacia Biotech).
Prostate-specific and developmental expression of the ARR 2 
PBCAT transgene
The levels of ARR 2 PBCAT gene expression in the four lines were compared in males and females ranging from 8 -9 weeks of age (at least five mice per group). Tissue samples from the anterior (AP), dorsolateral (DLP), and ventral prostate (VP) were microdissected for the determination of CAT activity. To determine tissue specificity, other tissues, including brain, spleen, thymus, heart, lung, liver, kidney, testes, muscle, adrenals, epididymis, and seminal vesicle from transgenic males, and brain, spleen, thymus, heart, lung, liver, kidney, muscle, adrenals, uterus, ovary, and oviduct from transgenic females, were analyzed for CAT activity. Proteins were extracted by homogenization in buffer containing 0.1 m Tris (pH 7.8) and 0.1% Triton X-100 buffer, and protein concentrations were determined by protein assay (Bio-Rad Laboratories, Inc., Richmond, CA). The CAT assay was performed as previously described (6), and results were expressed as disintegrations per min/mg protein Ϯ sd or, in cases of extremely high levels of CAT activity, per g protein.
To determine the developmental pattern of ARR 2 PBCAT gene expression before, during, and after sexual maturation, four to seven transgenic males per time point were killed at 1-14 weeks and 36 weeks of age. The AP, DLP, and VP were microdissected, and CAT activity for the individual lobes was determined as described above.
Immunohistochemical studies
Animals from line 3699b, aged 17 weeks (n ϭ 2) or 36 weeks (n ϭ 2), were killed, and the prostates were excised. The individual prostate lobes (AP, DP, LP, and VP) were dissected and fixed in 4% buffered formalin. After processing and embedding in paraffin, 5-m sections were cut for immunohistochemical detection of CAT protein.
Sections were deparaffinized, rehydrated, and placed in 0.05 m citrate buffer, pH 6.0. Antigenic sites were exposed by microwaving the sections for 30 min at 95-99 C before the removal of endogenous peroxidase activity with 3% H 2 O 2 . Nonspecific binding was blocked by incubating the sections with 1% DIG Blocking Reagent (Roche Molecular Biochemicals, Mannheim, Germany) in 100 mm Tris-HCl and 50 mm NaCl for 30 min. The sections were incubated with anti-CAT antibody (5Ј-3Ј, Inc., Boulder, CO) overnight at 4 C (1:400 dilution), washed in PBS (14 mm NaCl, 0.3 mm KCl, 1 mm Na 2 PO 4 , and 0.2 mm KH 2 PO 4 , pH 7.4), and incubated with biotinylated antirabbit IgG (1:300; DAKO Corp., Carpinteria, CA) at room temperature for 2 h. The sections were washed with PBS and incubated for 1 h with streptavidin (1:50; Vectastain Elite ABC Kit, Vector Laboratories, Inc., Burlingame, CA). After additional washes with PBS and 50 mm Tris-HCl (pH 7.4), peroxidase activity was detected using 3Ј,3Ј-diaminobenzidine tetrahydrochlorate (Liquid DAB Substrate-Chromagen System, DAKO Corp.). The reaction was terminated in distilled water, and the sections were counterstained with Harris hematoxylin (Surgipath, Richmond, VA), dehydrated, and permanently mounted with cytoseal XYL (Stephens Scientific, Kalamazoo, MI).
Hormonal regulation of ARR 2 PBCAT gene expression in the prostate
To determine the effects of androgen ablation and hormone treatment on ARR 2 PBCAT gene expression, transgenic males were castrated at 10 -11 weeks of age by the scrotal route. Sham-operated age-matched males served as controls (n ϭ 5). At 14 days postcastration, five castrated males per group received one of the following pellets sc. Steroid pellets (Innovative Research of America, Sarasota, FL) consisted of DHT (1.5 mg/pellet), DEX (1.5 mg/pellet), flutamide (25 mg/pellet), RU486 (5 mg/pellet), or placebo (5-mg pellet containing no hormone). After 7 days of treatment, the animals were killed, and CAT activity was measured in protein extracts obtained from the anterior, dorsolateral, and ventral lobes of the prostate. The effects of long-term castration on transgene expression in the absence of hormone treatment were determined by measuring the levels of CAT activity in four animals per group at each of the following time points: 14, 28, and 42 days postcastration.
Results
Multiple copies of the ARR produce enhanced steroid hormone regulation to the PB promoter
The present study used a number of minimal PB promoter constructs to determine the region required for prostatespecific gene expression and to determine whether glucocorticoid regulation could be added to androgenic regulation in transgenic mice. The first step in the construction of the minimal PB promoters was the removal of the sequences between Ϫ426 to Ϫ287, which are inhibitory to reporter gene expression in tissue culture (6) . Two resulting PB promoter-CAT constructs were generated, one that spanned the endogenous PB promoter sequence from Ϫ244 to ϩ28 bp (Ϫ244PBCAT), and the other from Ϫ286 to ϩ28 bp (Ϫ286PB-CAT). Next, one or two copies of the PB ARR were placed 5Ј to the Ϫ286PBCAT or to the shorter Ϫ244PBCAT construct. To determine whether both androgens and glucocorticoids had differential effects on the transcriptional regulation of these constructs, the induction of CAT activity was measured in the presence of AR and DHT or in the presence of GR and DEX, respectively, and compared with the basal level of CAT activity in the absence of hormone treatment in LNCaP and PC-3 cells.
Initially, CAT gene expression was determined in LNCaP cells in response to increasing concentrations of either DHT (Fig. 1A) or DEX (Fig. 1B) . As shown in Fig. 1 , the optimal concentration for steroid hormone-induced CAT gene expression was 10 Ϫ8 m DHT and 10 Ϫ8 m DEX for any construct tested. At these optimal steroid conditions, the Ϫ426/ ϩ28PBCAT construct was preferentially induced by DHT (11-fold) compared with DEX (1.8-fold) treatment, consistent with our previous observations about the biological activity of the wt PB promoter, which contains one copy of the ARR (6, 13) . When a second ARR DNA sequence was added upstream of the Ϫ244PB promoter [(ARR)Ϫ244PBCAT], CAT activity increased 88-fold in the presence of DHT, and a 285-fold increase in CAT activity was seen when a third copy of ARR was added [(ARR)(ARR)Ϫ244PBCAT; Fig. 1A] . Surprisingly, when LNCaP cells were transfected with (ARR)Ϫ244PBCAT plus the GR expression vector and treated with DEX, the levels of CAT gene activity increased dramatically to 137-fold when ARR copy number was doubled and 301-fold when ARR copy number was tripled (Fig.  1B) , compared with the 1.8-fold induction seen with Ϫ426/ ϩ28PBCAT. Therefore, the addition of one or two ARR DNA elements appears to alter biological activity in response to glucocorticoid hormone treatment in vitro.
The distance between the ARRs was also increased to determine whether this would affect the levels of reporter gene expression in response to steroid hormone treatment. The Ϫ286PB promoter was used so that the endogenous PB sequence from Ϫ286 to Ϫ244 could serve as a spacer. Thus, one ARR copy was added to the 5Ј-end of this construct to make (ARR)Ϫ286PBCAT, and an additional copy of ARR was added to generate the (ARR)(ARR)Ϫ286PBCAT construct. The CAT activity after 10 Ϫ8 m DHT treatment in-creased 229-fold when LNCaP cells were transfected with the AR expression vector and the (ARR)Ϫ286PBCAT construct (Fig. 1A) . In contrast to the 88-fold induction observed with (ARR)Ϫ244PBCAT, addition of the small spacer in (ARR)Ϫ286PBCAT appeared to facilitate the up-regulation of CAT gene expression, suggesting that the spacing alignment between the ARRs in the PB promoter and/or perhaps sequences within this region appears to be important for maximal induction of CAT gene transcription by androgens. The addition of a third ARR to make (ARR)(ARR)Ϫ 286PBCAT did not greatly improve the already high levels of CAT gene expression, resulting in a 214-fold rise in CAT activity (Fig. 1A) . The (ARR)Ϫ286PBCAT and (ARR)(ARR)Ϫ286PBCAT constructs were also tested for glucocorticoid induction by transfecting LNCaP cells with either construct together with the GR expression vector plus DEX treatment (Fig. 1B) . The CAT activity increased to 203-fold with (ARR)Ϫ286PBCAT and to 238-fold with (ARR)(ARR)Ϫ286PBCAT in the presence of glucocorticoid treatment. Again, these promoters were able to greatly increase responsiveness to glucocorticoid treatment compared with that seen with the parent construct Ϫ426/ϩ28PBCAT. Indeed, the activity of (ARR)Ϫ286PBCAT induced by glucocorticoids was virtually equivalent (203-fold) to that induced by DHT (229-fold).
As the largest rise in CAT gene expression in the LNCaP assay occurred when one or more ARR DNA fragments were linked to the basic PB promoter region, these constructs were further evaluated in a second human prostatic cell line. The results obtained in the PC-3 bioassay showed that the response to 10 Ϫ8 m DHT treatment of (ARR)-286PBCAT gene expression was 480-fold, and that of (ARR)(ARR)Ϫ286PBCAT gene expression was 324-fold ( Fig. 2A) . Treatment with DEX at 10 Ϫ8 m produced a 496-fold induction, similar to that observed with DHT treatment (Fig. 2B) . When a second ARR was added upstream of the Ϫ244PB promoter [(ARR)Ϫ244PBCAT], CAT activity increased 79-fold in the presence of DHT; however, only a 30-fold increase in CAT activity was seen when a third copy of ARR was added [(ARR)(ARR)Ϫ244PBCAT] ( Fig. 2A) . When PC-3 cells were transfected with (ARR)Ϫ244PBCAT plus the GR expression vector and treated with DEX, the levels of CAT gene activity rose from 5-to 66-fold when ARR copy number was doubled and 74-fold when ARR copy number was tripled (Fig. 2B) . Again, in a second prostatic cell line a similar trend was seen, and the data suggest that the close proximity of multiple AR-binding regions inhibits transgene expression in the presence of androgens and glucocorticoids.
Therefore, the spacing alignment between the ARRs in the PB promoter and/or perhaps sequences within this region appears to be important for maximal induction of CAT gene transcription by either androgens and/or glucocorticoids. Also, the addition of a third ARR DNA fragment did not greatly enhance gene expression in response to DHT or DEX treatment. As a result of these initial studies, the (ARR)Ϫ286PB was renamed ARR 2 PB and was further characterized in both cell culture and the transgenic animal model.
ARR 2 PB promotes basal levels of prostate-specific CAT expression in vitro
The specificity of the ARR 2 PB promoter to regulate transgene expression was determined in both prostatic and nonprostatic cell lines. The ARR 2 PBCAT construct was cotrans-
Comparison of androgen-and glucocorticoid-induced CAT activities in LNCaP cells. One or two copies of ARR were subcloned into Ϫ244/ϩ28 PBCAT and Ϫ286/ϩ28 PBCAT. Ϫ244/ϩ28 PBCAT and Ϫ286/ϩ28 PBCAT, which contain one copy of ARR between Ϫ244 to Ϫ96 bp, served as wild-type controls for both androgen-and glucocorticoid-induced activity. These constructs were cotransfected either with an AR expression vector into LNCaP cells and treated with 10 , or 10 Ϫ8 M DEX (B). The fold induction in response to hormone treatment was determined by comparing receptor gene activity induced by DHT or DEX to the corresponding baseline values in the absence of hormone. Activities and fold induction were measured in at least three determinations Ϯ SD, and all experiments were adjusted for transfection efficiency.
fected with the pRL-CMV vector (transfection efficiency control; Promega Corp.) into several prostatic (PC-3, LNCaP, and DU145) and nonprostatic (COS-1, MCF-7, PANC-1, and ZR-75-1) cell lines. Basal levels of CAT activity were detected in all three prostate cancer cell lines, whereas low to negligible levels of CAT activity were detected in the nonprostatic cell lines (Fig. 3) . Compared with PC-3 cells, the basal levels of CAT activity in ZR-75-1, MCF-7, COS-1, and PANC-1 cells were only 23%, 6.8%, 3.7%, and 1%, respectively. These results indicate that the ARR 2 PB promoter maintains a high degree of specificity for preferential expression in human prostate cancer cell lines.
ARR 2 PB selectively regulates steroid-hormone induced transcription
Induction of ARR 2 PB CAT activity in response to androgen and glucocorticoid treatment when cotransfected with the respective steroid expression vector was as high as 480-fold when tested in prostatic cell lines ( Fig. 2A) . For comparison, the AR or GR expression vectors were cotransfected into the nonprostatic COS-1, MCF-7, ZR-75-1, and PANC-1 cell lines (even if previous studies had reported that they contained steroid hormone receptors), and the cells were treated with or without 10 Ϫ8 m DHT (Fig. 4A ) or 10 Ϫ8 m DEX (Fig. 4B) . Androgen-induced transcription was highest in the PC-3 cells, followed by LNCaP cells and, lastly, DU145 cells. Lower levels of androgen-induced CAT activity were measured in MCF-7, PANC-1, and ZR-75-1 cells, and negligible levels were detected in COS-1 cells. The CAT gene expression in PC-3 and LNCaP cells was 2-to 5-fold higher than that determined in the other cell lines. In contrast, glucocorticoid treatment resulted in higher levels of ARR 2 PBCAT gene expression in DU145, COS-1, MCF-7, and PANC-1 cells, with the greatest change occurring in COS-1 cells (Fig. 4B) . The induction of CAT gene expression in PC-3, LNCaP, and
Evaluation of androgen-and glucocorticoid-induced activities in PC-3 cells. One or two copies of ARR were subcloned into Ϫ244/ϩ28 PBCAT or Ϫ286/ϩ28 PBCAT. Ϫ244/ϩ28 PBCAT and Ϫ286/ϩ28 PBCAT, which contain one copy of ARR between Ϫ244 to Ϫ96 bp, served as wild-type controls for both androgen-and glucocorticoid-induced activities. These constructs were cotransfected either with an AR expression vector into PC-3 cells and treated with 10 Ϫ8 M DHT (A) or with a GR expression vector and treated with 10 Ϫ8 M DEX (B). The fold induction in response to hormone treatment was determined by comparing receptor gene activity induced by DHT or DEX to the corresponding baseline value in the absence of hormone. The fold induction is shown in numbers above the histogram bars. Activities and fold induction were measured in at least three determinations Ϯ SD, and all experiments were adjusted for transfection efficiency. ZR-75-1 cells with DEX was similar to that seen with androgen treatment. Therefore, the addition of a second ARR to the endogenous PB ARR appears to impart new characteristics to the regulation of the CAT reporter gene. Although steroid-induced transcription was highest in PC-3 cells, ARR 2 PB has the ability to up-regulate transgene transcription in nonprostatic cells in response to androgen and glucocorticoid treatment.
ARR 2 PB promotes prostate-specific expression in vivo
The transient transfection assays demonstrated that the basal activity of ARR 2 PBCAT was strongly prostate cell specific and that the overexpression of AR or GR in nonprostatic cells resulted in the up-regulation of transgene expression with hormone treatment. To test whether the ARR 2 PB promoter could impart hormonal and developmental regulation in the prostate in a spatial and temporal manner, transgenic mice were made. Four transgenic founders (one female and three males) were identified using PCR analysis of tail DNA for the ARR 2 PBCAT transgene. The established lines were designated lines 3695, 3696, 3699, and 3706, respectively. The prostate lobes, seminal vesicles, epididymis, testis, brain, spleen, thymus, heart, lung, liver, muscle, adrenal glands, and kidney from male transgenic mice and the uterus, ovaries, oviduct, brain, spleen, thymus, heart, lung, liver, muscle, adrenal glands, and kidney from female transgenic mice were analyzed for CAT activity in all three male founders and in the F 1 offspring of the female founder at 25-30 weeks age (Table 1) .
High levels of CAT activity were detected in the prostate lobes, and very low to negligible CAT activity was measured in the seminal vesicles (Table 1) . No CAT activity was detected in any of the other tissues tested in males or females (data not shown). Although the levels of CAT activity varied in the prostatic lobes from the individual ARR 2 PBCAT founders, the CAT gene was expressed in all male founders and all male offspring in a prostate-specific manner. To determine the copy number of the transgene, mouse liver genomic DNA was isolated from the founder and the established ARR 2 PBCAT lines. Southern blot and DNA dot blot analyses were performed to estimate transgenic gene copy number. Line 3695 had 15 copies, line 3696 had 1 copy, and line 3706 had 2 copies of the ARR 2 PBCAT transgene ( Table  2 ). The founder 3699 split into 2 sublines in the F 1 generation, with line 3699a carrying 12 copies and line 3699b carrying 4 copies of ARR 2 PBCAT transgene.
After sexual maturation (at 9 -10 weeks of age), the lobes of the prostate and the seminal vesicles from at least 5 males/ line were analyzed for CAT gene expression ( Table 2 ). The levels of transgene expression were not directly related to transgene copy number. For example, line 3695, with a copy number of 15 genes, generated the lowest levels of CAT activity. We also compared CAT gene expression in agematched males from the ARR 2 PBCAT transgenic lines with other previously reported PB transgenic lines generated with the Ϫ426/ϩ28PBCAT, a line that gave the highest expression with this construct (7), and the 12-kb LPBCAT constructs (16) . The CAT activities in the AP, DLP, and VP of line 3699a were 2435%, 1436%, and 1754%, respectively, of those measured in the highest expressing Ϫ426/ϩ28PBCAT line. The CAT activities in the AP, DLP, and VP of the highest ARR 2 PBCAT-expressing line 3699a were 104%, 44%, and 43%, respectively, of those measured in the highest expressing LPBCAT line I. This demonstrated that the ARR 2 PB minimal promoter could induce significant levels of transgene expression. Only line 3695 showed low levels of transgene expression. This confirmed that although the composite ARR 2 PB promoter and the Ϫ426/ϩ28PB promoter are almost of the same length, the ARR 2 PB promoter is greatly superior in inducing high levels of transgene expression in a prostate-specific manner in transgenic mice.
The ARR 2 PBCAT line 3699b and line 3706 showed similar levels of CAT activity to that seen in the Ϫ426/ϩ28PBCAT line. In most of the transgenic lines, the highest levels of PB-directed transgene expression occurred in the VP, and the lowest levels occurred in the AP ( Table 2 ). The exception was line 3699b, in which transgene expression was highest in the DLP, similar to that observed in LPBCAT line VI (16) . These results suggest that the site of transgene integration and copy number not only affect the rate of transgene expression but may also influence the level of transgene expression in the individual lobes of the prostate.
Developmental regulation of ARR 2 PBCAT expression
PB gene expression is regulated developmentally by androgens, such that accumulation of PB mRNA increases in parallel with the rise in serum androgens and plateaus with the onset of sexual maturity. In line 3706, a moderately expressing line, at least four males were killed per time point at weekly intervals from 1-14 weeks and at 36 weeks of age. The prostates of the 1-week-old animals were too small to microdissect into individual lobes; therefore, CAT gene expression was measured as the total CAT activity per gland. In all other age groups, the lobes of the prostate were separated and analyzed individually (Fig. 5A) . As early as 1 week of age, CAT activity in the prostate of line 3706 mice was detectable at very low levels. Thereafter, CAT activity increased rapidly by 2-to 3-fold each week, reaching a peak activity of 35,550 Ϯ 3,233 dpm/min⅐mg protein in the AP by the seventh week, 54,210 Ϯ 3,348 dpm/min⅐mg protein in the DLP by the eighth week, and 80,770 Ϯ 6,053 dpm/min⅐mg protein in the VP by the eighth week. A small decrease in CAT activity was seen thereafter, but CAT activity was still maintained at this high level. Therefore, the increase in ARR 2 PBCAT gene expression followed the rise and plateau in serum androgen levels that occur during sexual maturation.
Transgene expression was also followed in a second line (line 3699b) to determine whether the site of transgene integration influenced the pattern of gene expression. Thus, CAT activity was determined in the individual lobes of the prostate from at least four males per group at 3, 5, 6, 9, 12, and 36 weeks of age (Fig. 5B) . In line 3699b, the levels of prostatic ARR 2 PBCAT gene expression increased 3.5-fold in the DLP and 4-fold in the VP with almost no change in CAT activity in the AP from 3-5 weeks of age. However, before reaching sexual maturity around 6 weeks of age, CAT transgene expression rapidly increased 10.6-fold (AP), 8-fold (DLP), and 5-fold in the VP. Between 6 -9 weeks of age, CAT activity continued to increase by 8.8-fold in the AP, 11.5-fold in the DLP, and 28.7-fold in the VP. Thereafter, CAT activity was maintained at very high levels to 36 weeks, the last data point tested. The patterns of transgene expression in the AP, DLP, and VP were similar in lines 3699b and 3706, with the CAT activity rising dramatically during puberty and then reaching a plateau with sexual maturity.
ARR 2 PB targets transgene expression to prostatic epithelial cells
In the construction of the composite ARR 2 PB promoter, the sequences between Ϫ426 and Ϫ286 were removed. This deletion did not affect prostate-specific expression in vivo (Table  1) ; however, the removal of these sequences could have influenced the prostatic epithelial cell-specific CAT expression observed previously in the Ϫ426/ϩ28PBCAT transgenic mice (7) . Therefore, the individual lobes of the prostate from male mice that were 17 and 36 weeks old (line 3699b) were microdissected, fixed in formalin, and processed for immunohistochemical studies using an anti-CAT antibody. The prostates showed specific positive immunoreactivity for the CAT protein only in the epithelial cells (Fig. 6 ). There were no differences in staining pattern or staining intensity for CAT protein between the two age groups. Control sections incubated with normal rabbit serum showed no positive The data are represented as CAT activity (disintegrations per min/mg protein), which was determined in each of the three individual male founders. As the founder of Line 3695 was a female, CAT activity was determined in three transgenic F 1 male offspring from that founder and is expressed as the mean Ϯ SD. No CAT activity was detected in any other tissue tested (adrenal gland, brain, epididymis, heart, kidney, liver, lung, muscle, spleen, testis, thymus, ovary, or uterus). The data are presented as CAT activity (disintegrations per min/mg protein), which was determined from at least five animals per group. In Table 2 , we compare the best expressing LPBCAT I and Ϫ426/ϩ28PBCAT lines to the four founders that established five lines for ARR 2 PB-CAT. In the LPBCAT transgenic lines, two of six founders (33%) expressed substantial levels of CAT activity (16) , whereas one of three Ϫ426/ϩ28PBCAT founders (33%) had higher levels of transgene expression (7) . In contrast, 80% of the ARR 2 PB CAT lines expressed high levels of CAT activity.
immunoreactivity in either the epithelium or the stroma. Very faint staining for CAT protein was observed in the anterior prostate (Fig. 6A) , consistent with the low levels of CAT activity determined for this lobe in line 3699b (Table 2 ). Figure 6 , B and C, shows positive CAT immunostaining in the dorsal and lateral prostate lobes, respectively. Although the amount of CAT activity was not individually determined for the dorsal and lateral lobes, the intensity of staining would suggest that the amount of CAT protein is greater in the lateral lobe (Fig. 6C ) than in the dorsal lobe (Fig. 6B) . This observation is consistent with the expression and staining pattern for the endogenous PB protein in the rodent prostate (8) . Figure 6D shows strong positive CAT immunostaining in the ventral prostate. In contrast, no positive immunoreactivity for CAT protein was detectable in the seminal vesicles (Fig. 6E ) or in controls treated with normal rabbit serum (Fig.  6F) . Positive immunoreactivity in the nucleus of some sections was observed in both control and CAT antibody-treated sections. This background immunoreactivity was not alleviated by different antigen retrieval techniques, new antibody batches, or changes in the staining method. Similar nuclear staining with this CAT antibody has been previously reported (18) .
Hormonal regulation of ARR 2 PBCAT transgene expression
The Ϫ426/ϩ28PB and LPB promoters confer androgen, but not glucocorticoid regulation, to transgene expression in transgenic animals (7, 16) . As the composite ARR 2 PB promoter is strongly inducible by both androgen and glucocorticoid in vitro, hormonal regulation by both steroid hormones was tested in vivo. Initially, the levels of transgene expression in response to castration were determined. Line 3699b males were castrated at 9 weeks of age, and CAT activity was measured at 14, 28, and 42 days postcastration (Fig. 7) . By 2 weeks postcastration, the levels of CAT activity fell to 51% in the AP, 19% in the DLP, and 24% in the VP compared with that observed in sham-operated controls (Fig. 7) . By 4 weeks postcastration, prostatic CAT levels decreased further, but only marginally, and by 6 weeks postcastration, CAT activity remained at 46% in the AP, 11% in the DLP, and 17% in the VP compared with that in the controls. Castration experiments using the Ϫ426/ϩ28PBCAT and LPBCAT transgenic mice revealed that CAT activity decreased to undetectable levels by 3 weeks (8, 16) . In contrast, postcastration transgene expression in the ARR 2 PB transgenic mice was maintained at appreciable levels even after 6 weeks of androgen deprivation.
Nine-week-old male animals were castrated and at 2 weeks postcastration were implanted with DHT, DEX, flutamide, RU486, or placebo pellets sc (see Materials and Methods). After 1 week of treatment, the mice were killed, and CAT activity was determined in the AP, DLP, and VP (Fig.  8) . In sexually mature male mice, by 2 weeks postcastration CAT activity had decreased to 17% of that in intact control animals in the DLP and VP, whereas CAT activity decreased to 38% in the AP compared with the levels observed in intact control animals. By 21 days postcastration, CAT activity had further decreased in the VP to 7% of that in control animals, but no further changes were observed in CAT activity in the AP and DLP. After implanting DHT pellets in mice 2 weeks postcastration, androgen treatment restored CAT activity to precastration levels within 1 week (AP, P Ͻ 0.002; DLP, P Ͻ 0.008; VP, P Ͻ 0.004). Compared with the placebo-treated group, treatment with the synthetic glucocorticoid DEX increased CAT gene expression to 42%, 22%, and 11% (AP, P Ͻ 0.01; DLP, P Ͻ 0.05; VP, P Ͻ 0.0001) of that in the intact control animals, suggesting that the addition of DEX supplemented any activity induced by adrenal glucocorticoids. In the flutamide (antiandrogen)-treated castrated mice, castration levels of CAT activity further decreased to 31%, 10%, and 6% (AP, P Ͻ 0.05; DLP, P Ͻ 0.05; VP, P Ͻ 0.062) of that in intact control animals. Compared with the placebo group, adrenal androgens were inhibited by flutamide treatment. The ant-glucocorticoid (RU486) treatment decreased CAT activity to 16%, 6%, and 4% (AP, P Ͻ 0.01; DLP, P Ͻ 0.02; VP, P Ͻ 0.035) of that in intact control animals. Compared with 3699b (B) were killed, and the prostate lobes were dissected and frozen at Ϫ70 C. Individual lobes of 1-week-old animals could not be dissected; therefore, the values represent the whole prostate. Each time point represents the mean CAT activity of four or five animals. In A, time points were taken weekly starting at 1 week of age to 16 weeks of age. Twenty weeks later the last time point was added. In B, time points included 2, 3, 5, 6, 9, 12, and 36 weeks of age. Values are presented as the mean Ϯ SD. Prostatic lobes are as follows: Ⅺ, anterior lobe; ࡗ, dorsolateral lobe; E, ventral lobe.
the placebo group, the blocking of adrenal glucocorticoids further down-regulated CAT gene expression in the prostate of castrated mice. This study indicates that unlike the LPB or Ϫ426/ϩ28PB promoter constructs, the composite ARR 2 PB promoter is now regulated by both androgens and glucocorticoids in vivo.
Discussion
In this study we describe a novel third generation PB promoter, ARR 2 PB, which targets high prostate-specific transgene expression. In contrast to previous PB promoter constructs, ARR 2 PB is more consistently expressed at high levels in the prostatic epithelium and can be regulated by both androgens and glucocorticoids. Therefore, ARR 2 PB has greater potential as a tool in the development of transgenic mouse models, and as a potential targeting promoter in the development of gene therapy vectors for the treatment of prostate cancer.
Several androgen-regulated prostate-specific genes have been identified, and these could become the stepping stones for identifying other prostate-specific regulatory proteins that may be important in prostate morphogenesis. Although the presence of a functional AR is a critical event in the development and differentiation of the prostate, its presence in many tissues in both males and females indicates that it is not sufficient to explain prostate-specific gene expression. We have shown that the rat PB promoter targets the prostate of transgenic mice (7, 16) . Similarly, the human prostatespecific antigen (PSA) gene is expressed in a highly prostatespecific manner in man. A large 6-kb 5Ј-flanking region (19) and a 14-kb genomic PSA fragment (20) target the prostate of transgenic mice, but a smaller 600-bp PSA promoter fragment is not prostate specific (21) .
Transgenic animal studies have determined that bases Ϫ426 to ϩ28 of the endogenous PB promoter are sufficient to target prostate-specific transgene expression (7). As a result, researchers have been analyzing this promoter fragment to define potential prostate-specific elements. Analysis of this promoter fragment has centered around transient transfection assays in prostatic and nonprostatic cell lines. Within the Ϫ426/ϩ28PB promoter resides the ARR (Ϫ244/Ϫ96 bp) of the PB gene (12) , which contains two AR-binding sites, ARBS-1 at Ϫ236 to Ϫ223 bp and ARBS-2 at Ϫ140 to Ϫ117 bp (7) . The size of this ARR regulatory element suggests that transcription factors other than androgens may interact with the AR to contribute to prostate-specific gene expression. Analysis of the PB promoter by Patrikainen et al. revealed that the PB sequences between positions Ϫ278 to Ϫ240 bp were critical for both androgen-and prostate-specific gene regulation in cell culture, and they concluded that an important transcription factor-binding site at position Ϫ251 to Ϫ240 bp was integral for determining tissue specificity (22) . Caution must be exercised in interpreting transient transfection into prostatic and nonprostatic cell lines as a measure of tissue specificity, as expression of the PB promoter in nonprostatic cells can be induced by the cotransfection of steroid receptors (23) . Interpretation of data generated in vitro assumes that 1) the critical regulatory factors that confer prostate-specific gene expression are present in prostate cancer cell lines, and 2) that transformed nonprostatic cells lines have not acquired the expression of regulatory factors critical for prostate-specific gene expression. Unfortunately, neither of these assumptions can be confirmed because the critical regulatory factors that govern prostate-specific gene expression have not been identified. Furthermore, normal prostatic cells cannot be maintained in cell culture, and therefore, we have to rely upon established prostate cancer cell lines to perform these studies. Therefore, the definitive test of tissue specificity is the transgenic mouse model.
The ARR 2 PB promoter conferred prostate-specific transgene expression that was developmentally and hormonally regulated in transgenic mice. These results were consistent in four separate transgenic lines. Indeed, the new ARR 2 PB promoter was highly effective, resulting in high levels of transgene expression in four of the five established lines (80%). No CAT activity was measured in any other tissue tested, thus confirming that ARR 2 PB contained the elements required for prostate-specific gene expression. In the Ϫ426/ϩ28PBCAT transgenic mice, one of three founders (33%) had relatively high levels of transgene expression (7), whereas in LPBCAT transgenic mice, two of six founders (33%) showed high levels of transgene expression (16) . In vivo, the new small composite ARR 2 PB promoter could increase CAT activity in the prostate up to 1436 -2435% greater than that measured with the highest Ϫ426/ϩ28PBCAT-expressing transgenic line. Similarly, expression was comparable to that observed in the highest expressing LPBCAT line. Thus, the ARR 2 PB construct further narrows down the prostate-specific cis-acting element as residing between Ϫ286 to ϩ28 bp of the PB promoter and indicates that the strong hormone-responsive In most transgenic animal models, the PB constructs target higher transgene expression to the ventral lobe, where the endogenous PB protein is expressed at lower levels. The dorsolateral prostate, which actually expresses the endogenous PB protein at the highest level, generally expresses lower levels of the transgene. These observations suggest that the lobe-specific DNA sequences are missing from these PB constructs, but prostate-specific sequences are distinct and included. However, the ARR 2 PBCAT line 3699b does show lobe-specific expression of the transgene, suggesting that the sequences required for lobe-specific expression are present in our constructs; however, the site of transgene integration into the genome may override these signals. Similarly, the levels of transgene expression, which are not consistent with transgene copy number, may be affected by the site of transgene integration through silencing. We have previously reported this silencing effect on the Ϫ426/ϩ28PB and LPB promoters (7, 16) . Furthermore, numerous transgenes in tandem may condense into euchromatin, thereby silencing transcription through interactions between the repeats (24, 25) . In addition, line 3699 split at the F 1 generation to establish 3699a (12 gene copies) and 3699b (4 gene copies). Subsequent studies with line 3699b suggest that this line appears to have undergone further changes in regulation since the F 1 males were first analyzed, as future generations now show increased transgene expression. This may reflect DNA imprinting, which would alter transgene expression if the methylation pattern at the site of integration changed.
Transient transfection and transgenic mouse studies have previously shown that the PB promoter in the wild-type conformation confers androgen selectivity over other steroid hormones (6, 7, 16, 26 -28) . In this study we have characterized the probasin ARR by combining two or three probasin ARRs. Surprisingly, this combination altered steroid hormone specificity such that transgene expression was now regulated by glucocorticoids in addition to androgens in both cell culture and transgenic mice. This novel characteristic was unexpected, because a single ARR sequence confers strong androgenic regulation of transgenes (13) .
An androgen response element (ARE) was previously defined as having the identical canonical sequence and activity as the MMTV GRE. Specificity for AR and GR binding was believed to result from the interactions of the AR or GR with other coactivators. Probasin ARBSs can bind the AR, but each site alone functions poorly as an ARE (12, 13) . The combination of ARBS-1 and ARBS-2 forms the ARR, which now regulates androgen-induced gene transcription in a cooperative manner (12, 13) . Notably, these binding sites can differentiate between the AR and GR when they are in the wt configuration (12, 13) . Furthermore, ARBS-2 is the first DNAbinding element that has been shown to be selective for transcriptional regulation by the AR (6, 12, 15, 29) . Recently, AREs have been redefined as low affinity AR-binding sites, and multiple AREs are now believed to function cooperatively to regulate transcription in response to androgen treatment (3, 12, 30) .
DNA binding studies have shown that ARBS-1 and ARBS-2 bind the AR selectively (12) and that the Ϫ426/ ϩ28PB promoter is transcriptionally regulated by the AR with weak activity for the GR in vitro (6) . Transgenic mouse studies using the Ϫ426/ϩ28PB and LPB have also determined that no functional GRE resides within these PB promoter constructs (7, 16, 26 -28) . Comparison of the Ϫ426/ ϩ28PB and ARR 2 PB promoters in LNCaP cells in a doseresponse curve to androgens and glucocorticoids confirmed that the Ϫ426/ϩ28PB promoter is preferentially induced by androgens (11-fold) over glucocorticoids (1.8-fold), and that overall this promoter has very weak induction of transcription. In contrast, the ARR 2 PB promoter in LNCaP cells showed strong induction by androgens (229-fold) and near equal induction by glucocorticoids (203-fold). Clearly, the discriminating nature between AR and GR does involve precise cis-DNA elements (12, 14, 15) ; however, changing the arrangement of these elements alters their activity, most likely by changing the cooperative effects between receptors and other corepressors and/or coactivators. Thus, the increased sensitivity to glucocorticoids does not appear to be promoter specific, but, rather, is due to the interactions between the multiple ARRs. It is possible that the weak individual interactions of the GR for one ARR are further stabilized by having multiple copies present in tandem, thereby allowing the cooperative interaction between these enhancer regions. The strong induction seen with the ARR 2 PB promoter in vitro suggests that transcriptional regulation by this promoter in vivo would be distinctly different from that seen with the Ϫ426/ϩ28PB promoter. It is important to note that the cell culture experiments use transformed prostate cells cotransfected with a GR expression vector; this would result in of thousands of copies of GR DNA per cell. This would most likely achieve higher levels of the steroid receptor in vitro than existing levels in vivo in normal prostatic cells. In vivo, castration induces prostatic apoptosis by which the VP regresses to about 1/10th, and the DLP regresses to about 1/5th of its original size, suggesting that epithelial cells from these two lobes respond differently to androgen. The remaining atrophic epithelial cells may have lost androgenregulated cofactors that are important for regulation of the probasin promoter. Thus, the administration of DEX to castrated mice may not be able to induce the necessary androgen regulated cofactors that are required for ARR 2 PB transgene expression. Therefore, either or both explanations could account for the strong glucocorticoid effects observed in vitro that are not duplicated in vivo.
Previous castration studies in the Ϫ426/ϩ28PBCAT or LPBCAT transgenic mice showed that prostatic CAT activity dropped to undetectable levels by 3 weeks postcastration (7, 16) . Similarly, the current castration study using ARR 2 PBCAT mice demonstrates that removal of androgens decreases CAT activity, whereas treatment with DHT restores prostatic CAT activity to precastration levels. In contrast to the Ϫ426/ϩ28PBCAT or LPBCAT transgenic mice, relatively high levels of CAT activity were still measurable in the prostate of ARR 2 PBCAT mice 6 weeks postcastration, suggesting that other factors could maintain levels of transgene expression. Treatment of castrated ARR 2 PBCAT mice with flutamide further reduced prostatic CAT activity compared to the placebo group, suggesting that flutamide could inhibit low levels of adrenal androgens. However, the ad-renal androgens alone were not sufficient to explain the continued transgene expression after castration.
In vitro experiments indicated that glucocorticoids regulated transgene expression; therefore, it is possible that the continued CAT expression after castration could be due to adrenal glucocorticoids. To test this hypothesis, pellets containing either DEX or the antiglucocorticoid, RU486, were administered to castrated mice. DEX treatment increased CAT activity (P Ͻ 0.05) in the prostate of castrated mice, whereas RU486 decreased CAT activity (P Ͻ 0.05) over and above that seen with flutamide. Thus, ARR 2 PB gene expression can be regulated by both androgens and glucocorticoids in vivo.
Gene therapy using prostate-specific promoters to target viral vectors to prostate cancer cells has been proposed as a new treatment for prostate cancer patients that have failed androgen deprivation therapy. Even though greater than 80% of patients show a favorable response to androgen deprivation as measured by tumor regression and a decrease in serum PSA levels, the duration of response is usually 2-3 yr (31, 32) . A number of potential mechanisms involving the AR have been proposed as reasons for the failure of androgen deprivation therapy (33-40). These observations indicate that the progression of prostate cancer may still involve an active AR. In gene therapy constructs that use an androgendriven promoter, such as the PB and PSA promoters, it may be possible to take advantage of this active AR in relapsed patients. However, it would be unacceptable to treat these men with androgens to induce an androgen-dependant viral vector, because androgen treatment would also drive prostate cancer growth. This presents a major problem in using an androgen-regulated prostate-specific promoter for gene therapy.
However, men who fail androgen deprivation therapy are often treated with glucocorticoids because it improves the quality of life, and a decrease in serum PSA levels has also been reported (41, 42). As glucocorticoid treatment is currently an acceptable therapy, it could potentially be used to induce transcription of an ARR 2 PB therapeutic gene in a prostate-specific manner for the treatment of prostate cancer. Thus, the glucocorticoid-inducible ARR 2 PB promoter may provide a novel strategy for regulating transgene expression in the development of gene therapy vectors for the treatment of prostate cancer.
In conclusion, the ARR 2 PB promoter maintains prostate, epithelial cell specificity in vivo, suggesting that the sequence from Ϫ286 to ϩ28 bp of the endogenous PB promoter retains the DNA sequences necessary for prostate-specific transgene expression. This new ARR 2 PB composite promoter provides major advantages over previous constructs. First, the composite promoter is highly consistent in generating transgenic lines with high levels of transgene expression (80%) compared with the Ϫ426/ϩ28PB and LPB promoters (33%). This is advantageous because if only a single transgenic line is generated, it is impossible to determine the effects of the site of integration on tissue specificity or, if no transgene expression occurs, to determine whether the site of integration or the actual transgene construct resulted in inactivity. Further, if the transgenic line has low levels of transgene expression, it may be difficult to obtain a prostatic phenotype. Second, the ARR 2 PB promoter is small enough to link to any transgene in viral vectors for the development of therapeutic gene therapy in the treatment of prostate cancer. The added glucocorticoid regulation via this composite promoter makes it a valuable tool for the treatment of prostate cancer patients that have failed androgen deprivation therapy.
